Bronchodilator reversibility in patients with asthma and persistent airflow limitation - Authors' reply

Lancet Respir Med. 2022 Nov;10(11):e96. doi: 10.1016/S2213-2600(22)00366-6.

Authors

Tessa M Kole¹, Huib A M Kerstjens², Maarten van den Berge²; ATLANTIS, UBIOPRED, CADSET contributors

Affiliations

¹ Department of Pulmonary Disease and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen 9713GZ, Netherlands. Electronic address: t.m.kole@umcg.nl.
² Department of Pulmonary Disease and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen 9713GZ, Netherlands.

PMID: 36332641
DOI: 10.1016/S2213-2600(22)00366-6

No abstract available

Publication types

Letter
Comment

MeSH terms

Asthma* / drug therapy
Bronchodilator Agents* / therapeutic use
Forced Expiratory Volume
Humans
Lung

Substances

Bronchodilator Agents